lobbying_activities: 3246304
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3246304 | efda9ea2-2f51-4a0a-97bd-c33e29a1dc7e | Q3 | FORBES-TATE | 400976792 | PHRMA | 2024 | third_quarter | PHA | Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2024-10-17T20:55:14-04:00 |